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 CURRENTOPINION Therapeutic strategies for C9orf72 amyotrophic
lateral sclerosis and frontotemporal dementia
Guillaume M. Hautberguea,b,c,, John D. Clearyd,e,f,, Shu Guod,e,f, and Laura
P.W. Ranumd,e,f,g,h
Purpose of review
An intronic G4C2 expansion mutation in C9orf72 is the most common genetic cause of amyotrophic lateral
sclerosis and frontotemporal dementia (C9-ALS/FTD). Although there are currently no treatments for this
insidious, fatal disease, intense research has led to promising therapeutic strategies, which will be
discussed here.
Recent findings
Therapeutic strategies for C9-ALS/FTD have primarily focused on reducing the toxic effects of mutant
expansion RNAs or the dipeptide repeat proteins (DPRs). The pathogenic effects of G4C2 expansion
transcripts have been targeted using approaches aimed at promoting their degradation, inhibiting nuclear
export or silencing transcription. Other promising strategies include immunotherapy to reduce the DPRs
themselves, reducing RAN translation, removing the repeats using DNA or RNA editing and manipulation
of downstream disease-altered stress granule pathways. Finally, understanding the molecular triggers that
lead to pheno-conversion may lead to opportunities that can delay symptomatic disease onset.
Summary
A large body of evidence implicates RAN-translated DPRs as a main driver of C9-ALS/FTD. Promising
therapeutic strategies for these devastating diseases are being rapidly developed with several approaches
already in or approaching clinical trials.
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INTRODUCTION
AGGGGCC hexanucleotide repeat expansion in the
first intron of C9ORF72 causes the most common
forms of familial amyotrophic lateral sclerosis (ALS)
and frontotemporal dementia (FTD) [1,2], geneti-
cally linking these two clinically distinct adult-onset
neurodegenerative disorders. C9ORF72 ALS, FTD or
both ALS and FTD can occur in individual patients
and within families [3]. C9-ALS/FTD patients typi-
cally have hundreds to thousands of G4C2G2C4
repeats, while shorter tracts of 2–24 repeats are
present in unaffected people [1,2]. ALS is character-
ized by motor neuron loss, muscle atrophy, progres-
sive paralysis and usually death within 2–5 years of
onset [4]. In FTD, degeneration of neurons in the
frontal and anterior temporal lobes can result in
personality changes such as apathy, loss of empathy,
disinhibition and executive function deficits [4].
Therapeutic options are limited and there are no
current treatment options that substantially change
the course of C9ORF72 ALS or FTD. The standard of
care includes the antiglutamatergic drug riluzole for
ALS [5] and the antidepressant fluoxetine or a
related compound for FTD [6]. In 2017, the free-
radical scavenger drug edaravone was approved for
use in ALS patients [7]. Unfortunately, none of these
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REVIEW
treatments improve motor or cognitive deficits;
however, riluzole and edaravone have been shown
to modestly slow disease progression in some
ALS patients.
Similar to other microsatellite expansion disor-
ders [8,9], the C9ORF72 G4C2G2C4 mutation is bi-
directionally transcribed and sense G4C2 and anti-
sense G2C4 expansion transcripts form RNA foci and
produce repeat associated non-AUG (RAN) proteins
[10–15]. Proposed disease mechanisms include
toxic effects of the expansion RNAs [1,16]; toxic
effects of sense (poly-GA, GR, GP) and antisense
(poly-PR, PA, GP) dipeptide RAN proteins [10,12–
14] and haploinsufficiency of the C9ORF72 protein
[17,18]. Overall, RAN proteins, particularly GA, GR
and PR, have been shown to be toxic in a number of
cell culture and animal models (for reviews [19,20]).
The discovery of the C9ORF72 expansion as the
most commongenetic cause of ALS and FTD [1,2] has
fuelled an interdisciplinaryworldwide research effort
to understand the mechanisms and develop thera-
pies for this disorder. C9ORF72 expansions cause
nearly 40% of familial and 6–8% of sporadic ALS
cases and nearly 18% of familial and 6% of sporadic
FTD cases [21,22
&
] in European populations but are
relatively rare in Asia [23]. The relatively large num-
bers of C9-ALS/FTD patients worldwide, combined
with multiple emerging therapeutic strategies have
positioned C9-ALS/FTD well for breakthrough ther-
apy development. Emerging therapeutic strategies
include targeting and removing the expanded
repeats; degrading, or preventing expression of
expansion transcripts; reducing toxic RAN proteins;
and modulating downstream affected pathways
including nucleocytoplasmic transport and stress
granules (Fig. 1). These strategies and additional
efforts to understand key molecular and physiologi-
cal changes that trigger disease may provide insights
that will lead to better diseasemanagement and help





Almost immediately following the discovery of the
C9ORF72 expansion mutation, efforts to develop
antisense oligonucleotide (ASO) drugs to knock-
down the repeat expansion RNAs began. These
nucleic acid based drugs are chemically modified,
and in some applications take advantage of the
nuclear RNase H1 pathway to degrade double-
stranded sequences that form when ASOs bind to
targeted gene transcripts [24
&&
]. For C9ORF72, spe-
cific ASOs were shown to selectively reduce sense
G4C2 RNA foci in patient cells without reducing the
levels of C9ORF72 mRNA [11,16]. BAC transgenic
mice treated with single-dose ASOs that selectively
target sense expansion RNAs but not mRNAs encod-
ing C9ORF72 protein, decreased sense RNA foci and
sense DPRs and improved behavioural abnormali-
ties [25]. Together, these results paved the way for a
phase I clinical trial to test the safety, tolerability
and pharmacokinetics of the Ionis/Biogen BIIB078
ASO in adults with C9ORF72 ALS (NCT03626012).
More recently, stereopure ASOs were shown to
increase RNAse H activity in vitro and in vivo com-
pared with stereorandom ASOs [26]. A lead candi-
date stereopure ASO showed selective degradation
of sense G4C2 expansion containing transcripts
without reducing the variant 2 isoform which lacks
the repeat. Treatment of BAC transgenic mice with
these ASOs reduced RNA foci and RAN GP proteins
but not C9ORF72 protein levels. In addition, these
oligonucleotides selectively protected iPSC-derived
motor neurons harbouring C9ORF72-expansion
mutations from glutamate-induced toxicity [27
&&
].
In an alternative approach, miRNAs targeting sense
C9ORF72-repeat transcripts using adeno-associated
virus serotype 5 (AAV5) delivery, reduced levels of
sense expansion transcripts and RNA foci in FTD




miRNA-depletion of SOD1 was recently reported in
two patients with SOD1-ALS [29
&&
], providing proof-
of-concept data that intrathecally delivered micro-
RNAs can be used as a potential treatment strategy
for ALS.
KEY POINTS
 Hexanucleotide repeat expansions in the C9ORF72
gene are the most common known genetic cause of
ALS and FTD, a spectrum of debilitating and incurable
neurodegenerative diseases.
 Repeat associated non-AUG (RAN) translation, which
leads to the production of dipeptide repeat proteins, is
a major driver of neuronal injury and disease.
 A number of therapeutic strategies aimed at reducing
the impact of expansion transcripts, RAN proteins,
nuclear transport deficits or stress granule biology have
shown efficacy in preclinical models of disease.
 Approaches aimed at modifying environmental factors
and lifestyle are promising complementary avenues for
improving the primary care of patients.
 Intense research efforts have resulted in several clinical
trials and others are expected to start soon.
Motor neuron disease
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Inhibiting transcription of C9-expansion
transcripts
Several different strategies are being actively pur-
sued to decrease the transcription of C9-repeat
expansion transcripts. For example, SUPT4H,
SUPT5H and RNA polymerase II associated factor
1 complex (PAF1C) are transcription factors that
play important roles in the elongation of RNAs
containing expanded repeats [30,31]. Decreased
expression of SPT4 encoded by SUPT4H was shown
to decrease the levels of sense and antisense
C9ORF72 expansion transcripts and GP-RAN pro-
teins in Caenorhabditis elegans, Drosophila and
iPSC-derived models of C9ORF72-ALS/FTD and to
ameliorate neurodegenerative phenotypes in Dro-
sophila [32]. Similarly, depletion of PAF1C reduced
expression of G4C2 expansion RNAs and poly (GR)
in aDrosophilamodel [31]. Although interesting, the
therapeutic potential of these strategies may be
limited by off-target effects [33
&
].
In other approaches, CRISPR-Cas9 deletion of
the promoter region driving expression of the
C9ORF72 repeat-containing transcript isoforms 1
and 3 led to the efficient reduction in expression
levels of all three sense DPRs in C9-ALS patient-
derived motor neurons [34
&
]. Pinto et al. [35]
showed targeting C9ORF72 expansions at the
DNA level using deactivated Cas9 (dCas9) effi-
ciently inhibits transcription and reduced the levels
of GP RAN protein in reporter cells. Similarly, use of
RNA-targeting deactivated-Cas9 (RCas9) allows
degradation of C9ORF72 expansion transcripts in
cell models [36], although it is possible that this
strategy also blocks transcription by binding of the
dCas9-PIN-gRNA to the DNA repeats as in dCas9
strategy.
FIGURE 1. Cellular consequences and therapeutic approaches for C9ORF72-ALS/FTD. C9-ALS/FTD affects a wide variety of
downstream cellular pathways with different therapeutic approaches (green boxes) targeting pathogenic C9 RNAs and RAN
DPRs as well as downstream pathways. External factors (bottom red bar) can also influence cellular events and combined with
lifestyle changes (bottom green bar) may affect disease onset and progression. Some content modified from Servier Medical
Art (smart.servier.com) under creative commons license.
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Although there is great hope that decreasing the
levels of G4C2 expansion transcripts will be suffi-
cient to improve disease, several studies suggest that
it will be important to increase efforts to also target
antisense transcripts. For example, antisense RNA
foci preferentially accumulate in regions of disease
in a C9ORF72 BAC transgenic mouse model suggest-
ing antisense expansion RNAs or RAN proteins may
be more toxic than their corresponding sense prod-
ucts [37]. Additionally, ASOs that target sense
C9ORF72 expansion transcripts did not correct
widespread transcriptomic defects found in
patient-derived cells [11], suggesting strategies tar-
geting both transcripts may offer the best outcomes.
IMMUNOTHERAPY STRATEGIES
TARGETING RAN PROTEINS
There is strong evidence that RANDPRs, particularly
GA, GR and PR, are one of themain drivers of disease
(for reviews [19,20]) and hence decreasing their
levels is an attractive therapeutic approach. Several
immunotherapy approaches have focused on the
GA RAN proteins. In patient fibroblasts and primary
neurons, a-GA antibodies reduced GA aggregate
formation and blocked aggregate seeding activity
of cerebellar extracts from C9ORF72 autopsy tissue
[38]. Vaccination of GA-overexpression mice with
ovalbumin-(GA)10 peptides elicited the production
of a-GA antibodies, lowered GA protein levels and
prevented microglial activation and motor deficits
[39
&&
]. Using BAC transgenic mice that express sense
and antisense transcripts and multiple types of RAN
proteins, Nguyen et al. [40
&&
] showed passive immu-
notherapy with a-GA antibodies improved behav-
ioural deficits, increased survival and decreased
neuroinflammation and motor neuron loss. These
peripherally injected antibodies crossed the blood
brain barrier and co-localizedwithGAprotein aggre-
gates. Glycosylation of the Fc antibody region was
important for cell entry and GA proteins were
reduced in a TRIM-21-, proteosome-, and autoph-
agy-dependent manner [40
&&
]. In addition to reduc-
ing GA, the a-GA1 treatment surprisingly also
reduced GP and GR proteins, likely through
increased proteosome function. No changes in sense
or antisense RNA levels or foci were observed in a-
GA1 treated mice providing strong support that




DECREASING RAN PROTEIN LEVELS
Several groups have shown that activation of the
integrated stress response (ISR) and increased p-
eIF2a levels increase RAN translation [41–44,45
&&
].
Zu et al. [45
&&
] showed G4C2 and other repeat expan-
sion RNAs activate ISR protein kinase R (PKR) and
that PKR inhibition dramatically reduces RAN pro-
tein levels. Zu et al. [45
&&
] went on to show inhibition
of PKR using AAV-delivered dominant negative PKR-
K296R or the FDA-approved drug metformin,
decreased p-PKR and RAN protein levels and
improved behaviour and neuropathology in C9
BAC transgenic mice without changing sense or
antisense transcript levels. There is an active clinical
trial to test the safety of metformin in C9ORF72 ALS
patients and its effects on RAN protein levels
(NCT04220021). Inhibition of the SRSF1-dependent
nuclear export of both sense and antisense
C9ORF72-repeat transcripts and subsequent RAN
translation was also reported as a promising gene
therapy approach in preclinical models including
patient-derived motor neurons andDrosophilamod-
els of disease [46].
Other strategies to reduce RAN protein levels
include stimulating their clearance. For example,
heat shock protein family B member 8 (HSPB8)
has been shown to promote autophagy-mediated
removal of several misfolded C9 RAN proteins from
motor neurons [47]. Although the therapeutic
potential of this approach is uncertain, clearance
of protein aggregates could have applications for a
wide variety of neurodegenerative diseases. Taken
together, these data support the therapeutic poten-
tial of targeting RAN translation and RAN proteins
for C9-ALS/FTD as well as other RAN protein
associated disorders.
TARGETING THE GENOMIC C9ORF72
HEXANUCLEOTIDE-REPEATS
Correcting the GGGGCCGGCCCC repeat expan-
sion mutation should theoretically address all dele-
terious mutation effects, including effects from
sense and antisense RNAs and DPRs. Current gene
editing techniques have focused primarily on clus-
tered regular interspaced short palindromic repeats
(CRISPR)-associated (Cas) systems, although appli-
cation to C9-ALS/FTD has so far been limited
[48,49
&
]. In iPSC-cells, CRISPR/Cas9 editing and
homology-directed repair (HDR) replacement of
the expansion with a wildtype repeat resulted in
restoration of C9ORF72 gene expression and meth-
ylation and reduced intron retention and down-
stream pathogenic phenotypes [49
&
]. In iPSC-
derived motor neurons, CRISPR/Cas9 correction
abolished GluA1 AMPA receptor (AMPAR) mediated
excitotoxicity [48]. Targeting regions outside the
repeat or the entire C9ORF72 gene have also been
tested with varying degrees of success. For example,
deletion of a portion of the upstream C9ORF72
Motor neuron disease
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promoter prevents the production of exon 1a expan-




this approach does not prevent expression of anti-
sense RNA and associated antisense DPRs, which
likely contribute to disease. Although correcting
the expansion mutation seems to be a straight-for-
ward idea, adequate delivery to affected tissues/cell
types and the accuracy of emerging CRISPR based




TDP43 plays important roles in transcriptional reg-
ulation, alternative splicing of pre-mRNAs, axonal
transport of mRNAs, translational regulation and
miRNA processing. TDP-43 also associates with
stress granules [50], which constitute dynamic
membrane-less organelles that promote cell survival
by halting translation of nonessential mRNAs in
response to cellular stress [51]. Stress granules are
composed of RNA and RNA-binding proteins with
low complexity domains (LCDs) that mediate liq-
uid-liquid phase separation (LLPS). Mutations in the
LCDs domains of TDP43, ataxin-2 and other RNA-
binding proteins involved in ALS/FTD stimulate
their self-assemblies leading to the formation of
persistent cytoplasmic stress granules that leave
aggregated proteins that may contribute to disease
[52]. Interestingly, arginine-rich C9ORF72 DPRs
impair stress granule assembly dynamics by under-
going LLPS, further inducing the phase separation of
stress granule proteins [53]. Overexpression of GFP-
polyGR proteins impairs stress granules and protein
translation in mice deficits [54]. TDP-43 proteinop-
athy, aggregation of stress granule proteins (G3BP1,
ataxin-2), nucleocytoplasmic defects, neuronal loss
and motor/cognitive deficits were observed in an
AAV-driven overexpression mouse model of
expanded G4C2 repeats [55]. DPRs also promote
nucleocytoplasmic transport disruption by stimu-
lating the recruitment of nucleocytoplasmic trans-
port proteins to stress granules [56]. In fact, many
nucleocytoplasmic transport factors are localized to
stress granules when exposed to stressors or mutant
proteins implicated in ALS pathogenesis, leading to
impaired nucleocytoplasmic transport [56].
TARGETING NUCLEOCYTOPLASMIC
TRANSPORT DEFICITS
In 2015, Zhang et al. [57] demonstrated increased
nuclear export inC9ORF72ALS iPSNmodels showed
abnormal cytoplasmic RanGTPase accumulation.
RanGTPase is important in nucleocytoplasmic pro-
tein transport (reviewed in [58]). Abnormal expres-
sion and localization of nuclear pore proteins are
found in C9ORF72 autopsy tissue and patient-
derived iPSNs [57,59]. Modulating the expression
of nuclear pore proteins or transport-associated pro-
teins affects G4C2 expansion transcripts and argi-
nine containing RAN protein toxicity [57,60,61].
Overexpression of importin or inhibition of nuclear
export with RNA inhibition of (Exportin 1) XPO1 or
pharmacologically ablating XPO1 function using
KPT-276 rescued C9ORF72 toxicity in the
C9ORF72 fly model [57]. Another XPO1 inhibitor,
KPT-350, designed by KaryopharmTherapeutics and
acquired by Biogen (BIIB100), has been used in
preclinical studies of many neurological diseases





Neurotrophic factors (NTFs), a family of biomole-
cules that support neuronal growth, survival and
differentiation, have been explored for decades as
therapeutic strategies for neurodegenerative dis-
eases [66
&
], including ALS. Various NTFs have been
tested in preclinical rodent models of SOD1-ALS,
including brain-derived neurotrophic factor
(BDNF), insulin-like growth factor 1 (IGF-1) and
vascular endothelial growth factor (VEGF). Small
molecule agonist of the BDNF receptor [67], VEGF
injections [68,69], lentiviral and AAV-mediated
delivery of NTFs [70–73] and stem cell therapy of
NTF secreting cells [74–82] have shown promise in
SOD ALS models. Despite these promising results,
including several ongoing clinical trials [66
&
], there
have been no direct studies looking at NTF thera-
peutics in C9-ALS/FTD. Although some NTF clinical
trials in ALS likely include C9-ALS/FTD participants,
it will be important, given the unique disease mech-
anisms of C9-ALS/FTD, to directly examine NTF
specifically in the C9 context.
PREVENTION AND FUNCTIONAL
MANAGEMENT
For C9-ALS/FTD, there is a relatively long period of
apparent good health prior to disease onset, which
most often occur in the fourth or fifth decade of life,
and extending this period of good health has been
gaining considerable attention. Both preclinical ani-
mal studies and human studies demonstrate that
moderate exercise regimens improve functionality
and ameliorate disease symptoms for ALS in general
(reviewed in [83]). However, the role of exercise is
complex. In a retrospective study, patient-reported
Therapeutic strategies for C9ORF72-ALS/FTD Hautbergue et al.
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exercise history was inversely correlated with age-of-
onset in C9ORF72 but not other forms of ALS [84],
although additional studies that examine the
impact of specific types of exercise will be impor-
tant. Targeted trainingmay be key. In a randomized,
sham-controlled clinical trial, Plowman et al.
[85,86
&&
] showed that expiratory muscle-strength
training is well tolerated in ALS patients and
improved bulbar function in a longitudinal
C9ORF72 case-study and also in larger cohorts of
genetically undefined ALS patients. Longitudinal
studies suggest that lifestyle modifications (e.g.
smoking cessation, maintaining a healthy BMI) at
a younger age may lower the risk of developing ALS
[87
&&
]. Recent studies have identified C9ORF72
expansions in 1.6% (n¼8/487) of cases with possi-
ble idiopathic normal pressure hydrocephalus
(iNPH) but not in control cases (n¼0/432) aged
more than 65years. Clinically significant shunt
response was detected in six out of seven shunted
C9ORF72 expansion carriers. Additional studies are
needed to understand the frequency of NPH in
C9ORF72 expansion carriers and the potential util-
ity of shunts to drain excess cerebrospinal fluid in
these patients. Patient lifestyle, co-morbid diseases
and environmental factors (Fig. 1) can influence
cellular events, making it important to study and
understand external factors that may influence dis-
ease. Dietary studies specific to C9-ALS/FTD are rare,
although a larger study focused on ALS in general
has demonstrated that increasing fruit and vegeta-
ble associated fibre, antioxidants and carotenes was
associated with improved function [88]. The results
of many of these broader ALS studies are compli-
cated by the complex genetics and phenotypic pre-
sentation of ALS, increasing the call for preventive
and lifestyle studies that focus on C9ORF72 or other
single ALS mutations.
STRATIFICATION AND EFFICIENCY IN
CLINICAL TRIALS
Although there are multiple therapeutic approaches
for C9-ALS/FTD in the preclinical pipeline, there are
only two C9-ALS/FTD specific clinical trials regis-
tered in ClinicalTrials.gov: an ASO-based clinical
trial of BIIB078 (Biogen), which targets C9ORF72
expansion containing transcripts for ASO-induced
RNase H-mediated degradation (NCT03626012);
and a clinical trial (NCT04220021), to test the safety
and tolerability of metformin in C9ORF72 ALS
patients and the drug’s ability to decrease RAN
protein levels. Several additional trials are open to
but not specific to C9-ALS/FTD patients. These
include a phase 1 clinical trial of BIIB100 to reduce
excessive nuclear export (NCT03945279) in C9 and
other ALS patients, will examine the safety, tolera-
bility, pharmacokinetics (PK) and pharmacodynam-
ics (PD) of the drug. A phase 2 clinical trial
examining the safety, tolerability, PK and PD of
AL001, a recombinant human antihuman sortilin
(SORT1) monoclonal IgG1 antibody in FTD patients
with either granulin or C9ORF72 mutations
(NCT03987295). Sortilin is a type I membrane gly-
coprotein involved in proganulin trafficking that is
expressed in the central nervous system [89]. Fron-
totemporal degeneration can be caused bymutation
in the progranulin (GRN) gene or the C9ORF72
hexanucleotide expansion repeat and there are rare
patients withmutations in both [90]. More recently,
Wave Life Sciences has been reported to seek regu-
latory approval for WVE-004, an investigational
stereopure ASO targeting the expansion transcript
of C9-ALS/FTD [27
&&
]. It is interesting to note the
current batch of clinical trials, which focus on dif-
ferent pathogenic pathways, could potentially be
used together.
CONCLUSION
Despite the mechanistic and clinical complexity of
C9ORF72 ALS/FTD, intense research efforts over the
10 years since the expansion mutation was identi-
fied have led to a remarkable number of novel
therapeutic approaches in preclinical and clinical
trial stages. The breadth and diversity of these
approaches provide hope for C9-ALS/FTD patients,
who currently have limited therapeutic options
focused on supportive care. The pace of research
focused on the root causes of this disease has been
remarkable and is likely to accelerate and uncover
additional new therapeutic targets and treatment
strategies that will significantly impact C9-ALS/FTD
and the larger family of repeat expansion disorders.
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